Estrogen therapy and COVID-19, generic levothyroxine


March 09, 2022

1 minute read

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

A recent study showed that postmenopausal women who were prescribed estrogen therapy had a significantly lower risk of death after contracting COVID-19 compared to a control group. It was the first story in endocrinology last week.

The second main article assessed the effects of switching from generic levothyroxine preparations on hormone levels. Guidelines published by the American Thyroid Association advise providers to avoid switching between generic levothyroxine products from different manufacturers, leading providers to prescribe brand name levothyroxine to most adults with hypothyroidism, according to the researchers. However, a new study found that switching from generic levothyroxine preparations did not significantly affect thyroid-stimulating hormone levels.

Source: Adobe Stock

Read these and many more endocrinology stories below:

Estrogen therapy halved risk of death from COVID-19 in postmenopausal women

Menopausal hormone therapy significantly reduced the risks of death from COVID-19 in postmenopausal women, according to data from a national registry-based study. Read more.

Switching from generic levothyroxine preparations does not affect thyroid hormone levels

According to the study data, adults who switch generic levothyroxine preparations from one manufacturer to another have no difference in average thyroid-stimulating hormone levels compared to those who do not switch. Read more.

CGM Achieves Breakthrough Device Designation for Hospital Use

The FDA has granted Breakthrough Device Designation for use of Dexcom’s Continuous Glucose Monitoring System in a hospital setting, according to an industry press release. Read more.

Effect of vitamin D-calcium supplement on tibia similar to placebo

According to data from a study published in BONE. Read more.

Non-profit organization offers low-cost biosimilar insulins regardless of insurance status

The nonprofit generic pharmaceutical company Civica will manufacture and distribute biosimilar versions of three widely prescribed insulins for $30 per vial or $55 for five pens, according to a JDRF press release. Read more.